Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allarity TherapeuticsFRA:C6D0 26 FCF Yield % is -92.84 as of Jul. 14, 2026. GuruFocus rates FRA:C6D0 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Allarity Therapeutics ranks worse than 89.85% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Allarity Therapeutics FCF Yield % Related Terms
Allarity Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Allarity Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:C6D0 vs NCEL, LPCN, PTN: FCF Yield % Comparison
For the Biotechnology subindustry, Allarity Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allarity Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allarity Therapeutics (FRA:C6D0) has a FCF Yield % of -92.84 as of Jul. 14, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Allarity Therapeutics and its competitors. According to the industry distribution chart, Allarity Therapeutics ranks #1266 out of 1409 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Allarity Therapeutics' FCF Yield % too high?
Allarity Therapeutics' current FCF Yield % is -92.84. Based on the distribution chart, Allarity Therapeutics ranks #1266 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' FCF Yield % compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #1266 out of 1409 companies for FCF Yield %. This places Allarity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current FCF Yield % is -92.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (FRA:C6D0) has a current FCF Yield % of -92.84. The current FCF Yield % is -92.84. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Allarity Therapeutics (FRA:C6D0), the current FCF Yield % is -92.84 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score
Get the complete analysis for FRA:C6D0
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C6D0 has been successfully added to your 
